LT2729130T - Darunaviro derinių kompozicijos - Google Patents
Darunaviro derinių kompozicijosInfo
- Publication number
- LT2729130T LT2729130T LTEP12738060.8T LT12738060T LT2729130T LT 2729130 T LT2729130 T LT 2729130T LT 12738060 T LT12738060 T LT 12738060T LT 2729130 T LT2729130 T LT 2729130T
- Authority
- LT
- Lithuania
- Prior art keywords
- darunavir
- combination formulations
- formulations
- combination
- darunavir combination
- Prior art date
Links
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 title 1
- 229960005107 darunavir Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11173067 | 2011-07-07 | ||
| PCT/EP2012/063249 WO2013004818A1 (en) | 2011-07-07 | 2012-07-06 | Darunavir combination formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2729130T true LT2729130T (lt) | 2018-01-10 |
Family
ID=46551505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP12738060.8T LT2729130T (lt) | 2011-07-07 | 2012-07-06 | Darunaviro derinių kompozicijos |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140142070A1 (enExample) |
| EP (1) | EP2729130B1 (enExample) |
| JP (1) | JP6122427B2 (enExample) |
| KR (1) | KR102058097B1 (enExample) |
| CN (1) | CN103826616B (enExample) |
| AU (1) | AU2012280198B2 (enExample) |
| BR (1) | BR112014000290B1 (enExample) |
| CA (1) | CA2838659C (enExample) |
| CY (1) | CY1121999T1 (enExample) |
| DK (1) | DK2729130T3 (enExample) |
| EA (1) | EA026587B1 (enExample) |
| ES (1) | ES2651212T3 (enExample) |
| HR (1) | HRP20171889T1 (enExample) |
| HU (1) | HUE035241T2 (enExample) |
| IL (1) | IL229933A (enExample) |
| LT (1) | LT2729130T (enExample) |
| MX (1) | MX343689B (enExample) |
| NO (1) | NO2729130T3 (enExample) |
| PL (1) | PL2729130T3 (enExample) |
| PT (1) | PT2729130T (enExample) |
| RS (1) | RS56667B1 (enExample) |
| SI (1) | SI2729130T1 (enExample) |
| SM (1) | SMT201700574T1 (enExample) |
| WO (1) | WO2013004818A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2729130T (pt) | 2011-07-07 | 2017-12-13 | Gilead Sciences Inc | Formulações de combinação de darunavir |
| WO2013130766A1 (en) * | 2012-03-01 | 2013-09-06 | Gilead Sciences, Inc. | Spray dried formulations |
| NZ709260A (en) | 2012-12-21 | 2016-07-29 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| CN113546052A (zh) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | 治疗人免疫缺陷病毒的治疗组合物 |
| BR112019002132A2 (pt) | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composições anti-retrovirais |
| WO2018029566A1 (en) * | 2016-08-08 | 2018-02-15 | Hetero Labs Limited | A high drug loaded tablet composition for treating hiv |
| BR112019002120A2 (pt) * | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composição anti-retroviral de várias classes |
| EP3518935A1 (en) * | 2016-09-27 | 2019-08-07 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| BR112020000842A2 (pt) | 2017-07-20 | 2020-07-21 | Janssen Sciences Ireland Unlimited Company | composições e métodos para tratamento do hiv |
| US20200101093A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Sciences Ireland Unlimited Company | Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV |
| US20210290590A1 (en) | 2020-03-13 | 2021-09-23 | Janssen Sciences Ireland Unlimited Company | Methods of treating subjects infected with hiv |
| CN119700779B (zh) * | 2024-11-28 | 2025-11-04 | 安徽贝克生物制药有限公司 | 一种达芦那韦和考比司他复合片剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006030A1 (en) | 1993-08-24 | 1995-03-02 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
| US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| AU771780B2 (en) | 1998-06-23 | 2004-04-01 | Board Of Trustees Of The University Of Illinois, The | Fitness assay and associated methods |
| AR037797A1 (es) | 2001-12-12 | 2004-12-01 | Tibotec Pharm Ltd | Combinacion de inhibidores de proteasa dependientes del citocromo p450 |
| AU2003271740B2 (en) | 2002-05-16 | 2010-05-13 | Janssen R&D Ireland | Pseudopolymorphic forms of a HIV protease inhibitor |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| MX339668B (es) | 2006-05-30 | 2016-06-02 | Janssen Pharmaceutica N V * | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. |
| US20080039428A1 (en) * | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
| PL2049506T5 (pl) | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| MX2009004439A (es) * | 2006-10-25 | 2009-05-11 | Mcneil Ppc Inc | Composicion de ibuprofeno. |
| EP3150586B1 (en) | 2007-02-23 | 2020-01-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| RU2010102067A (ru) * | 2007-06-25 | 2011-07-27 | Тиботек Фармасьютикалз (Ie) | Комбинированные композиции, включающие дарунавир и этравирин |
| AR069539A1 (es) * | 2007-07-25 | 2010-02-03 | Tibotec Pharm Ltd | Avances respecto de las formulaciones de comprimidos contra el vih |
| CA2706328C (en) | 2007-11-20 | 2016-04-19 | Janssen Pharmaceutica N.V. | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor |
| PA8809601A1 (es) * | 2007-12-24 | 2009-07-23 | Cipla Ltd | Combinación anti-retroviral |
| EP2296633B1 (en) * | 2008-05-02 | 2015-09-30 | Gilead Sciences, Inc. | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| NZ594214A (en) * | 2009-02-06 | 2013-05-31 | Gilead Sciences Inc | Tablets comprising cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil fumarate for combination therapy |
| PT2477992T (pt) * | 2009-09-17 | 2017-03-20 | Mylan Laboratories Ltd | Processos para a preparação de darunavir e a forma amorfa do mesmo |
| US20130195978A1 (en) | 2010-05-10 | 2013-08-01 | Hetero Research Foundation | Darunavir Compositions |
| PT2729130T (pt) | 2011-07-07 | 2017-12-13 | Gilead Sciences Inc | Formulações de combinação de darunavir |
| HUE030341T2 (en) | 2011-07-07 | 2017-05-29 | Janssen Sciences Ireland Uc | Darunavir preparations |
| AU2012327170A1 (en) | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
| JP2018502118A (ja) | 2015-01-03 | 2018-01-25 | マイラン・ラボラトリーズ・リミテッドＭｙｌａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ | 非晶質ヘミフマル酸テノホビルアラフェナミドおよびその予備混合物を調製するプロセス |
-
2012
- 2012-07-06 PT PT127380608T patent/PT2729130T/pt unknown
- 2012-07-06 KR KR1020147000092A patent/KR102058097B1/ko active Active
- 2012-07-06 HU HUE12738060A patent/HUE035241T2/en unknown
- 2012-07-06 SM SM20170574T patent/SMT201700574T1/it unknown
- 2012-07-06 BR BR112014000290-8A patent/BR112014000290B1/pt active IP Right Grant
- 2012-07-06 EP EP12738060.8A patent/EP2729130B1/en active Active
- 2012-07-06 SI SI201231141T patent/SI2729130T1/en unknown
- 2012-07-06 CA CA2838659A patent/CA2838659C/en active Active
- 2012-07-06 DK DK12738060.8T patent/DK2729130T3/en active
- 2012-07-06 EA EA201490222A patent/EA026587B1/ru unknown
- 2012-07-06 US US14/131,282 patent/US20140142070A1/en not_active Abandoned
- 2012-07-06 WO PCT/EP2012/063249 patent/WO2013004818A1/en not_active Ceased
- 2012-07-06 PL PL12738060T patent/PL2729130T3/pl unknown
- 2012-07-06 RS RS20171244A patent/RS56667B1/sr unknown
- 2012-07-06 JP JP2014517822A patent/JP6122427B2/ja active Active
- 2012-07-06 ES ES12738060.8T patent/ES2651212T3/es active Active
- 2012-07-06 NO NO12738060A patent/NO2729130T3/no unknown
- 2012-07-06 LT LTEP12738060.8T patent/LT2729130T/lt unknown
- 2012-07-06 MX MX2013015199A patent/MX343689B/es active IP Right Grant
- 2012-07-06 CN CN201280033554.0A patent/CN103826616B/zh active Active
- 2012-07-06 HR HRP20171889TT patent/HRP20171889T1/hr unknown
- 2012-07-06 AU AU2012280198A patent/AU2012280198B2/en active Active
-
2013
- 2013-12-17 IL IL229933A patent/IL229933A/en active IP Right Grant
-
2017
- 2017-12-05 CY CY20171101267T patent/CY1121999T1/el unknown
-
2019
- 2019-11-27 US US16/697,888 patent/US11654150B2/en active Active
-
2023
- 2023-05-05 US US18/313,266 patent/US20230302024A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269682A (en) | New immunoconjugates | |
| PL2729130T3 (pl) | Preparaty kombinowane darunawiru | |
| IL229700B (en) | Dronvir formulations | |
| ZA201300194B (en) | Formulations | |
| GB201110193D0 (en) | Formulations | |
| GB201013513D0 (en) | Formulations | |
| GB201110278D0 (en) | Formulations | |
| IL227905A0 (en) | Toroidal pharmaceutical compositions | |
| EP2782585A4 (en) | ANTIVIRAL PREPARATIONS | |
| ZA201300196B (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201102795D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201104049D0 (en) | Formulations | |
| GB201105410D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201111578D0 (en) | Pharmeutical formulations | |
| GB201206178D0 (en) | Formulations | |
| GB201018645D0 (en) | Formulations | |
| GB201007959D0 (en) | Formulations | |
| GB201018649D0 (en) | Formulations | |
| GB201018648D0 (en) | Formulations | |
| GB201018647D0 (en) | Formulations |